1. Ling L, Wei Z, Yu H, Tong X, Zheng S, Yang J, et al. Effect of Convalescent PlasmaTherapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA – J Am Med Assoc. 2020;E1–11.
2. Ministerio de Salud. Costa Rica. Situación Nacional Covid. 2020. Disponible en : https://www.ministeriodesalud.go.cr/index.php/centro-de-prensa/noticias/741-noticias-2020/1725-situacion-nacional-covid-19 visitado 30 agosto 2020
3. Chenguang S, Zhaoqin W, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma. JAMA – J Am Med Assoc. 2020; 323(16):1582–9.
4. World Health Organization. Protecting the blood supply during infectious disease outbreaks: guidance for national blood services. 2020 [cited 2020 Sep 1]. Disponible en: https://www.who.int/publications/i/item/protecting-the-blood-supply-during-infectious-disease-outbreaks-guidance-for-national-blood-services
5. World Health Organization. Guidance on maintaining a safe and adequate blood supply during the coronavirus disease 2019 (COVID-19) pandemic and on the collection of COVID-19 convalescent plasma. World Heal Organ Interim Guid. 2020;July(10):1–6.
6. Beth S, BenAvram D. Association Bulletin #20-02 – Recommendations for Providing a Safe Environment for Blood Donation During the COVID-19 Epidemic. 2020. 2–3. Disponoble en: http://www.aabb.org/programs/publications/bulletins/Documents/ab20-02.pdf
7. Ministerio de Salud. Costa Rica. Lineamientos para los Servicios de Sangre Públicos y Privados en el Marco de la Alerta Sanitaria por Coronavirus (COVID-19). 2020. Disponible en: https://www.ministeriodesalud.go.cr/sobre_ministerio/prensa/docs/lineamientos_tecnicos_servicios_sangre_marco_coronavirus_ v2_20032020.pdf
8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
9. Kwon SY, Kim EJ, Jung YS, Jang JS, Cho NS. Post-donation COVID-19 identification in blood donors. Vox Sang. 2020;1–2.
10. Katz LM. Is SARS-CoV-2 transfusion transmitted? Transfusion. 2020;60(6):1111–4.
11. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin Infect Dis. 2020:13–5. Disponible en: doi: 10.1093/cid/ciaa449
12. U.S. Food and Drugs Administration. Updated Information for Blood Establishments Regarding the Novel Coronavirus Outbreak. 2020. 1–3. Disponible en: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/updated-information-blood-establishments-regarding-novel-coronavirus-covid-19-outbreak
13. Molina-Ulloa S, Valerín-Cháves A. Lineamiento Técnico para la Recolección y Procesamiento de Plasma Convaleciente COVID-19 (PCC). 2020. Disponible en: https://www.ccss.sa.cr/web/coronavirus/assets/materiales/personal/lineamientos/250.pdf
14. Ou-Yang J, Li SJ, Bei C hua, He B, Chen J yan, Liang H qin, et al. Blood Donor Recruitment in Guangzhou, China, during the 2019 Novel Coronavirus (COVID-19) Epidemic. Transfusion. 2020. Abril:1–14.
15. Pagano MB, Hess JR, Tsang HC, Staley E, Gernsheimer T, Sen N, et al. Prepare to adapt: blood supply and transfusion support during the first 2 weeks of the 2019 novel coronavirus (COVID-19) pandemic affecting Washington State. Transfusion. 2020;60(5):908–11.
16. Wang Y, Han W, Pan L, Wang C, Liu Y, Hu W, et al. Impact of COVID-19 on blood centres in Zhejiang province China. Vox Sang. 2020;1–5.
17. U.S. Food and Drugs Administration. Revised recommendations for reducing the risk of Zika virus transmission by blood and blood components. Guidance for industry. 2020. Disponible en: http://www.aabb.org/programs/publications/bulletins/Documents/ab20-03.pdf
18. Beth Shaz, BenAvram D. Association Bulletin #20-03 – Emergent Standards to the 31st and 32nd editions of Standards for Blood Banks and Transfusion Services. 2020. Disponible en from: http://www.aabb.org/programs/publications/bulletins/Documents/ab20-03.pdf
19. Raturi M, Kusum A. The blood supply management amid the COVID-19 outbreak. Transfus Clin Biol. 2020;27(3):147–51. Disponible en: https://doi.org/10.1016/j.tracli.2020.04.002
20. Cai X, Ren M, Chen F, Li L, Lei H, Wang X. Blood transfusion during the COVID-19 outbreak. Blood Transfus. 2020;18(2):79–85.
21. Shander A, Goobie SM, Warner MA, Aapro M, Bisbe E, Perez-Calatayud AA, et al. Essential Role of Patient Blood Management in a Pandemic: A Call for Action. Anesth Analg. 2020;131(1):74–85.
22. Baron DM, Franchini M, Goobie SM, Javidroozi M, Klein AA, Lasocki S, et al. Patient blood management during the COVID–19 pandemic: a narrative review. Anaesthesia. 2020;75(8):1105–13.
23. Singh G, Nahirniak S, Arora R, Légaré J-F, Kanji H, Nagpal D, et al. Transfusion Thresholds for Adult Respiratory Extracorporeal Life Support: An Expert Consensus Document. Can J Cardiol. 2020;( July):10–3.
24. Stanworth SJ, New H V, Apelseth TO, Brunskill S, Cardigan R, Doree C, et al. Effects of the COVID-19 pandemic on supply and use of blood for transfusion. Lancet Haematol- 2020;3026(theme 2):1–9. Disponible en: http://dx.doi.org/10.1016/S2352-3026(20)30186-1
25. Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion. 2006;46(8):1279–85.
26. Dunbar NM, Yazer MH, Carey PM, Christie JD, Fadeyi EA, Fontaine MJ, et al. Safety of the use of group A plasma in trauma: the STAT study. Transfusion. 2017;57(8):1879–84.
27. Nickel RS, Margulies S, Frazer B, Luban NLC, Webb J. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic. Blood. 2020;135(25):2316–9.
28. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362(7):600–13.
29. Ljungman P, Mikulska M, de la Camara R, Basak GW, Chabannon C, Corbacioglu S, et al. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplant. 2020; Disponible en: http://dx.doi.org/10.1038/s41409-020-0919-0
30. Slichter SJ, Bolgiano D, Corson J, Jones MK, Christoffel T, Bailey SL, et al. Extended storage of buffy coat platelet concentrates in plasma or a platelet additive solution. Transfusion. 2014;54(9): 2283–91.
31. Stolla M, Fitzpatrick L, Gettinger I, Bailey SL, Pellham E, Christoffel T, et al. In vivo viability of extended 4°C-stored autologous apheresis platelets. Transfusion. 2018; 58(10): 2407–13.
32. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology. 2020;20: 363–74.
33. Wong CK, Lam CWK, Wu AKL, Ip WK, Lee NLS, Chan IHS, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004; 136(1): 95–103.
34. Hsueh-Limg J, Gan SKE, Bertoletti A, Tan YJ. Understanding the T cell immune response in SARS coronavirus infection. 2020, 1: Emerging Microbes and Infections. Taylor & Francis; 2012; 1(9); 23.
35. Tabibi S, Tabibi T, Conic RRZ, Banisaeed N, Streiff MB. Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients. Journal of Intensive Care Medicine. 2020;35: 827–35.
36. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5): 2620–9.
37. Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev. 2020;c7(6):998–1002.
38. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054–62.
39. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. The Lancet Haematology. 7; 2020: 438–40.
40. Gavriilaki E, Brodsky RA. Severe COVID‐19 infection and thrombotic microangiopathy: success does not come easily. Br J Haematol. 2020 Jun;189(6): 227–30.
41. Chauhan A, Wiffen L, Brown T. COVID‐19: a collision of complement, coagulation and inflammatory pathways. J Thromb Haemost. 2020; 0–3.
42. Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34(3):171–354.
43. Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel treatment approach to the novel coronavirus: An argument for the use of therapeutic plasma exchange for fulminant COVID-19. Critical Care. 2020; 24 (128).
44. Stahl K, Bode C, David S. First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19. Critical care. 2020; 24(363).
45. Gucyetmez B, Atalan HK, Sertdemir I, Cakir U, Telci L. Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study. Crit Care. 2020;24(1):1–4.
46. Khamis F, Al-Zakwani I, Al Hashmi S, Al Dowaiki S, Al Bahrani M, Pandak N, et al. Therapeutic Plasma Exchange in Adults with Severe COVID-19 Infection. Int J Infect Dis. 2020; 99: 214-218.
47. Kesici S, Yavuz S, Bayrakci B. Get rid of the bad first: Therapeutic plasma exchange with convalescent plasma for severe COVID-19. Proceedings of the National Academy of Sciences of the United States of America. National Academy of Sciences; 2020.(117): 12526–7.
48. Malkovsky M. Therapeutic Plasma Exchange-Neutralizing Antibody Combination Therapy for Severe Coronavirus Disease 2019. J Infect Dis. 2020 Jul; 222(3):509–10.
49. Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, et al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-2 Month Experience. medRxiv. 2020. Disponible en https://doi.org/10.1101/2020.08.12.20169359
50. Focosi D, Tang J, Anderson A, Tuccori M. Convalescent Plasma Therapy for Covid-19: State of the Art. Clin Microbiol Rev. 2020; 33(4):1–17.
51. Franchini M, Marano G, Velati C, Pati I, Pupella S, Liumbruno GM. Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy. Vox Sang. 2020; 116(1) 136-137.
52. Casadevall A, Joyner MJ, Pirofski LA. A Randomized Trial of Convalescent Plasma for COVID-19 – Potentially Hopeful Signals. JAMA – J Am Med Assoc. 2020; 324(5):455–7.
53. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020; 117(17): 9490–6.